Zelenoleucel by Marker Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Zelenoleucel is under clinical development by Marker Therapeutics and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zelenoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zelenoleucel overview

zelenoleucel (MT-401) is under development for the treatment of acute myelocytic leukemia, relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, sarcoma, breast cancer, pancreatic cancer, lymphoma, ovarian cancer. The therapeutic candidate is administered as intravenous infusion. The cellular immunotherapy constitutes donor derived multi tumor associated antigen (TAA)-specific T cells which act by targeting cancer cells which express WT1, PRAME, NY-ESO-1, Survivin tumor associated antigens. It is administered as an intravenous infusion.

Marker Therapeutics overview

Marker Therapeutics is a clinical-stage immuno-oncology company that carries out the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company’s pipeline products include MT-401, which is used for the treatment of post-transplant AML and MT-601, which is used for the treatment of advanced unresectable pancreatic cancer. It also provides Multi-Antigen Targeted (MultiTAA) technology that utilizes a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient’s blood. Marker Therapeutics carries out several clinical studies including acute myeloid leukemia, non-Hodgkin’s lymphoma, multiple myeloma and breast cancer. Marker Therapeutics is headquartered in Houston, Texas, the US.

For a complete picture of Zelenoleucel’s drug-specific PTSR and LoA scores, buy the report here.